On August 31, 2022, Yokoyama, Yuta; Nozawa, Eiji; Morita, Miho; Ishikawa, Emi; Mori, Takehiko; Sakurai, Masatoshi; Kikuchi, Taku; Matsuki, Eri; Yamazaki, Rie; Kataoka, Keisuke; Jibiki, Aya; Kawazoe, Hitoshi; Suzuki, Sayo; Nakamura, Tomonori published an article.Category: piperazines The title of the article was Simultaneous quantification of dasatinib, nilotinib, bosutinib, and ponatinib using high-performance liquid chromatography-Photodiode array detection. And the article contained the following:
Dasatinib, nilotinib, and bosutinib, second-generation tyrosine kinase inhibitors (TKIs), and ponatinib, a third-generation TKI, are approved pharmaceuticals used in the treatment of chronic myeloid leukemia (CML). Although liquid chromatog.-tandem mass spectrometry assays for simultaneous quantification of the four TKIs in human serum have been reported in the literature, a high-performance liquid chromatog. (HPLC) assay that simultaneously quantifies these compounds has not yet been developed. This study aims to establish and validate an efficient HPLC anal. method using a photodiode array (PDA) detector for the simultaneous quantification of the four TKIs. Calibration standards were prepared by serial dilution of serum samples containing the four TKIs, followed by solid-phase extraction The four TKIs were eluted in order within 10 min using a binary HPLC gradient system. The calibration ranges were 2-500 ng/mL for dasatinib, 100-5000 ng/mL for nilotinib, and 10-500 ng/mL for bosutinib and ponatinib. Intra-day and inter-day precision and accuracy values were found to be in accordance with the U. S. Food and Drug Administration guidelines. The recovery rates were 92.9%-96.0%, 80.7%-86.1%, 91.6%-99.0%, and 86.4%-92.6% for dasatinib, nilotinib, bosutinib, and ponatinib, resp. To the best of our knowledge, this is the first report of an HPLC-PDA anal. method that allows efficient simultaneous quantification of the four TKIs in the serum of patients with CML. We believe that the method developed herein can improve the efficiency of therapeutic drug monitoring in patients with CML in clin. practice. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Category: piperazines
The Article related to photodiode dasatinib nilotinib bosutinib ponatinib high performance liquid chromatog, chronic myeloid leukemia, high-performance liquid chromatography, photodiode array detector, tyrosine kinase inhibitor and other aspects.Category: piperazines
Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics